Roivant Sciences
Roivant Sciences is a biopharmaceutical company dedicated to advancing the development of innovative late-stage drug candidates and enhancing healthcare delivery. The company aims to expedite the process of bringing new medicines to patients while reducing associated costs, thereby benefiting the healthcare system. Roivant achieves this by creating specialized entities known as "Vants," which are agile biotech and healthcare technology companies that leverage unique talent sourcing and incentive alignment strategies. In addition to its focus on biopharmaceuticals, Roivant incubates discovery-stage companies and health technology startups that complement its core business. Among its commercial-stage drug candidates is VTAMA, a treatment for plaque psoriasis in adults, along with several other candidates, including Batoclimab, IMVT-1402, Brepocitinib, and Namilumab, which are at various stages of development.
Top Stages
11 past transactions
Zest Health
Seed Round in 2025
Founded in 2013, Zest Health develops a mobile application that connects users with medical experts, enables appointment scheduling, provides health information, and stores electronic health records. Its solution focuses on strategic buying, access to healthcare professionals, preventative care, and disease management programs.
Immunovant
Post in 2025
Immunovant is a clinical-stage biopharmaceutical company focused on developing monoclonal antibodies for treating autoimmune diseases. Its lead candidate, IMVT-1401, targets the neonatal Fc receptor (FcRn) and is in Phase II trials for myasthenia gravis, thyroid eye disease, and warm autoimmune hemolytic anemia.
Lokavant
Series A in 2022
Lokavant is an information technology company specializing in clinical trial intelligence. It provides real-time monitoring and anticipatory analytics to enhance the management of clinical trials. By leveraging advanced analytics and visualization techniques, Lokavant aims to facilitate rigorous analysis and proactive risk management, thereby simplifying the monitoring process for clinical trials. The company integrates artificial intelligence and human insights to deliver risk alerts and real-time visualizations, ensuring that stakeholders can make informed decisions throughout the trial lifecycle.
Medallion
Series B in 2021
Medallion is a San Francisco-based company founded in 2020 by Derek Lo, specializing in a network management platform tailored for the healthcare industry. The company offers an all-in-one solution for licensing, credentialing, and payer enrollment, aimed at simplifying the often cumbersome processes associated with healthcare paperwork. Its platform provides features such as primary source verification, continuing medical education tracking, and document management, enabling healthcare providers and telemedicine companies to minimize time spent on administrative tasks and focus more on patient care.
Gen-t
Pre Seed Round in 2021
Founded in 2021, Gen-t is a Brazilian company that develops a diverse genetic biobank for genomic research. It aims to represent Brazil's genetic diversity, fostering innovation in biotechnology and providing researchers with valuable data for developing medicines and treatments.
Immunovant
Post in 2021
Immunovant is a clinical-stage biopharmaceutical company focused on developing monoclonal antibodies for treating autoimmune diseases. Its lead candidate, IMVT-1401, targets the neonatal Fc receptor (FcRn) and is in Phase II trials for myasthenia gravis, thyroid eye disease, and warm autoimmune hemolytic anemia.
Silicon Therapeutics
Acquisition in 2021
Silicon Therapeutics is an innovative drug design and development company that utilizes a unique, physics-driven approach to advance biotechnology. By integrating computational methods with chemistry and biology research and development, the company aims to target previously deemed intractable protein targets for drug discovery. Its specialized platform leverages the innate immune system to simulate biological molecules according to physical laws, facilitating the prediction of interactions, energies, and conformational behaviors of drug targets. This technology provides a deeper understanding of the relationship between protein conformations and biological outcomes, positioning Silicon Therapeutics at the forefront of novel small molecule therapeutic development.
Datavant
Series B in 2020
Datavant is a health data platform company focused on securely connecting and organizing biomedical data to support drug development and clinical trials. It provides a privacy-preserving network that enables the secure exchange of health records across thousands of organizations, helping researchers and pharmaceutical developers access real-world data while protecting patient privacy. By structuring data for trial design and interpretation, the company aims to improve clinical outcomes and accelerate medical research.
Patara Pharma
Acquisition in 2018
Patara Pharma, Inc., established in 2013 and headquartered in San Diego, California, is a clinical-stage biotechnology company dedicated to developing therapeutics targeting debilitating allergic and inflammatory diseases affecting orphan or focused patient populations. Its lead product candidate, PA101B, is an immune modulator with mast cell stabilizing properties designed for treating chronic cough refractory to existing therapies, including individuals with idiopathic pulmonary fibrosis, and for managing indolent systemic mastocytosis, an orphan indication.
Datavant
Venture Round in 2018
Datavant is a health data platform company focused on securely connecting and organizing biomedical data to support drug development and clinical trials. It provides a privacy-preserving network that enables the secure exchange of health records across thousands of organizations, helping researchers and pharmaceutical developers access real-world data while protecting patient privacy. By structuring data for trial design and interpretation, the company aims to improve clinical outcomes and accelerate medical research.
Arbutus Biopharma
Post in 2018
Arbutus Biopharma is a biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for chronic hepatitis B infection. Its pipeline includes AB-836, AB-423, AB-729, and HBV RNA destabilizer, targeting different aspects of the virus's lifecycle. The company aims to achieve a functional cure by combining these therapies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.